Provided by Tiger Trade Technology Pte. Ltd.

Tyra Biosciences, Inc.

22.03
-1.5100-6.41%
Post-market: 22.170.1400+0.64%19:55 EDT
Volume:1.55M
Turnover:35.06M
Market Cap:1.31B
PE:-9.17
High:23.96
Open:23.63
Low:21.86
Close:23.54
52wk High:40.65
52wk Low:11.82
Shares:59.49M
Float Shares:35.21M
Volume Ratio:0.64
T/O Rate:4.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4031
EPS(LYR):-2.0125
ROE:-45.31%
ROA:-28.46%
PB:3.71
PE(LYR):-10.95

Loading ...

Tyra Biosciences Q1 EPS $(0.64) Misses $(0.59) Estimate

Benzinga Earnings
·
May 13

Tyra Biosciences Q1 FY26 net loss widens to $39.31 million

Reuters
·
May 13

Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

THOMSON REUTERS
·
May 13

Tyra Biosciences Inc: Cash, Cash Equivalents and Marketable Securities of $383.5 Mln at Q1 2026; Runway Into 2H 2028

THOMSON REUTERS
·
May 13

Tyra Biosciences Q1 EPS USD -0.64

THOMSON REUTERS
·
May 13

Tyra Biosciences Q1 Operating Expenses USD 41.998 Million

THOMSON REUTERS
·
May 13

Tyra Biosciences to present at BofA Securities Health Care Conference

Reuters
·
May 08

How TYRA-300 Bladder Cancer Data and New Trial Partnership Will Impact Tyra Biosciences (TYRA) Investors

Simply Wall St.
·
May 06

Does Tyra Biosciences (TYRA) Board Refresh and Dabogratinib Spotlight Reframe Its Pipeline Credibility?

Simply Wall St.
·
Apr 27

Tyra Biosciences director Habib J. Dable files initial beneficial ownership statement

Reuters
·
Apr 21

Tyra Biosciences announces annual shareholder meeting via webcast

Reuters
·
Apr 17

Tyra Biosciences appoints Habib Dable to board of directors

Reuters
·
Apr 17

Tyra Biosciences Announces Appointment of Habib Dable to Its Board of Directors

THOMSON REUTERS
·
Apr 17

Tyra Biosciences Advances Dabogratinib Trial in Niche Urothelial Cancer: What Investors Should Watch

TIPRANKS
·
Apr 17

This Tyra Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Benzinga
·
Apr 15

Guggenheim Initiates Tyra Bioscience at Buy With $54 Price Target

MT Newswires Live
·
Apr 15

Tyra Biosciences Initiated at Buy by Guggenheim

Dow Jones
·
Apr 15

Tyra Biosciences Inc : Guggenheim Initiates Coverage With Buy Rating; Target Price $54

THOMSON REUTERS
·
Apr 15

Tyra Biosciences initiated with a Buy at Guggenheim

TIPRANKS
·
Apr 15

Tyra Biosciences Initiated at Buy by Canaccord Genuity

Dow Jones
·
Apr 06